サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：強直性脊椎炎市場- 成長、将来展望、競合分析、2023～2031年
市場調査レポート
商品コード
1422211

強直性脊椎炎市場- 成長、将来展望、競合分析、2023～2031年

Ankylosing Spondylitis Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 114 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
強直性脊椎炎市場- 成長、将来展望、競合分析、2023～2031年
出版日: 2024年01月09日
発行: Acute Market Reports
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

強直性脊椎炎（AS）は、主に脊椎を侵し、痛み、こわばり、運動障害を引き起こす慢性炎症性疾患です。強直性脊椎炎市場は、生物学的療法の進歩、支援プログラムによる患者中心のアプローチ、早期診断につながる意識の高まりに後押しされ、2024年から2032年の予測期間中にCAGR 8.5％で成長すると予測されています。しかし、生物学的療法は高価であることが顕著な阻害要因となっています。市場セグメンテーションは、AS薬に対するダイナミックな嗜好と疾患有病率の地域差を反映しています。地域的には、北米が収益に大きく寄与している一方、アジア太平洋地域は高い成長の可能性を示しています。競合動向は、ノバルティス、アッヴィー、ヤンセンなどの主要企業が採用している戦略を浮き彫りにしています。これらの企業は、技術革新、患者サポート、世界市場拡大を活用して競争力を維持しています。強直性脊椎炎市場が2023年から予測期間である2032年まで進展する中で、この慢性炎症性疾患に罹患した人々の生活改善を継続的に成功させるためには、コストの障壁に対処し、患者中心のアプローチを維持し、地域的なニュアンスに適応することが重要です。

生物学的製剤の進歩

TNF阻害剤などの生物学的製剤の進歩は、この疾患の治療に大きく貢献しています。コセンティクス、ヒュミラ、エンブレルのような薬剤は、炎症を抑え、症状を管理し、AS患者の全体的なQOLを改善する効果を示しています。その証拠は、これらの生物学的療法がポジティブな影響を与えることを示す臨床試験や実臨床研究にあります。例えば、コセンティックスの有効性は、ASの症状および機能性の持続的改善において実証されています。これらの生物学的製剤はAS治療の最前線であり続け、その継続的な開発と採用が市場の成長に寄与しています。

患者中心のアプローチとサポートプログラム

患者中心のアプローチは、製薬企業が提供する包括的なサポートプログラムと相まって、強直性脊椎炎市場の原動力となっています。Simponi、Remicade、CimziaなどのAS治療薬を提供する企業は、患者が薬にアクセスし、副作用を管理し、治療計画を遵守するのを支援するサポートプログラムを開始しています。その証拠に、こうした支援プログラムが治療アドヒアランスや患者の転帰にプラスの影響を与えることを強調する患者の声や実体験があります。企業が患者の幸福と全人的ケアを優先し続ける中、患者中心のアプローチは市場の成長を維持する上で極めて重要な役割を果たすと予想されます。

認知度の向上と早期診断

強直性脊椎炎の認知度の高まりと早期診断への取り組みは、市場にプラスの影響を与えています。ヘルスケア団体、患者支援団体、製薬企業による取り組みが、この疾患の症状や早期介入の重要性に関する認知度向上に寄与しています。その証拠に、診断症例の増加や、ASの早期発見を目的としたスクリーニングプログラムの実施が見られます。早期診断により、タイムリーな介入と効果的な治療の開始が可能となり、より良い疾患管理につながります。啓蒙キャンペーンがヘルスケア専門家と一般市民の双方を教育し続けるにつれて、早期診断の傾向は持続し、AS市場の成長を促進すると予想されます。

生物学的製剤の高コスト

強直性脊椎炎の生物学的製剤による治療には高額な費用がかかるため、市場参入の大きな抑制要因となっています。コセンティクスやヒュミラのような薬剤は、その有効性にもかかわらず、患者にとってもヘルスケアシステムにとっても経済的負担が大きいです。その証拠に、生物学的治療の費用対効果の課題を浮き彫りにする経済評価や研究があります。経済的な負担は、一部の患者のアクセスを制限し、最適な疾患管理を妨げる可能性があります。患者支援プログラムは存在するが、生物学的製剤の高コストという包括的な問題に対処することは、効果的なAS治療への公平なアクセスを確保するために極めて重要です。

薬剤のセグメンテーションコセンティクス、ヒュミラ、エンブレルが市場を独占

2023年、強直性脊椎炎市場では、コセンティクス、ヒュミラ、エンブレルといった薬剤の売上が最も高いです。しかし、予測期間中（2024～2032年）の年間平均成長率（CAGR）が最も高いのはチムジアです。このダイナミックな成長の原動力となるのは、患者やヘルスケアプロバイダーの特殊な属性と進化する嗜好性です。ASの症状を管理し、患者の転帰を改善するシムジアの有効性は、研究および実世界のエビデンスによって裏付けられています。AS治療の情勢が進展するにつれて、安全性プロファイルや患者の反応などの要因に影響され、薬剤の嗜好が変化する可能性があります。

北米は引き続き世界リーダー

地域別では、北米が2023年の売上高に占める割合が最も高く、これは確立されたヘルスケアインフラと有病率の高さを反映しています。しかし、アジア太平洋地域は予測期間中に最も高いCAGRを示すと予測されています。その根拠は、アジア太平洋諸国におけるASに対する認識の高まり、ヘルスケアへのアクセスの改善、治療選択肢の進化にあります。こうした地理的動向は、疾患有病率、治療嗜好、ヘルスケアインフラの地域差に対応するための個別戦略の必要性を強調しています。

市場競争は予測期間中に激化へ

2023年、強直性脊椎炎市場の主要プレーヤーには、ノバルティス、アッヴィ、ヤンセン、アムジェン、UCB、ファイザー、イーライリリー・アンド・カンパニー、ジョンソン・エンド・ジョンソン・サービス、メルク・アンド・カンパニーなどが含まれます。これらの企業は、研究開発、患者支援活動、市場拡大努力など、多様な戦略を採用しています。その証拠に、新たな治療選択肢の継続的な開発、患者支援プログラム、ヘルスケア専門家や患者支援団体との協力関係があります。2023年現在、競合情勢は、各社が製品提供とサポート体制の強化に努めるダイナミックな市場であることを示しています。2023年の収益と予測期間（2024～2032年）の状況から、技術革新、患者中心のアプローチ、世界戦略が成功の鍵を握る競合環境が明らかになった。

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 強直性脊椎炎市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2023 vs 2032

第4章 強直性脊椎炎市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の強直性脊椎炎市場金額 2022-2032
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーパワー
    • バイヤーパワー
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的情勢
    • 経済情勢
    • テクノロジーの情勢
    • 法的情勢
    • 社会的情勢

第5章 強直性脊椎炎市場：薬剤別 2022-2032

  • 市場概要
  • 成長・収益分析：2023 vs 2032
  • 数量と価格の分析2022-2032
  • 市場セグメンテーション
    • コセンティクス
    • ヒュミラ
    • シンポニ
    • レミケード
    • エンブレル
    • シムジア
    • その他

第6章 強直性脊椎炎市場：流通チャネル別 2022-2032

  • 市場概要
  • 成長・収益分析：2023 vs 2032
  • 数量と価格の分析2022-2032
  • 市場セグメンテーション
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第7章 北米の強直性脊椎炎市場 2022-2032

  • 市場概要
  • 強直性脊椎炎市場：薬剤別 2022-2032
  • 強直性脊椎炎市場：流通チャネル別 2022-2032
  • 強直性脊椎炎市場：地域別 2022-2032
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国と欧州連合の強直性脊椎炎市場 2022-2032

  • 市場概要
  • 強直性脊椎炎市場：薬剤別 2022-2032
  • 強直性脊椎炎市場：流通チャネル別 2022-2032
  • 強直性脊椎炎市場：地域別 2022-2032
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋の強直性脊椎炎市場 2022-2032

  • 市場概要
  • 強直性脊椎炎市場：薬剤別 2022-2032
  • 強直性脊椎炎市場：流通チャネル別 2022-2032
  • 強直性脊椎炎市場：地域別 2022-2032
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカの強直性脊椎炎市場 2022-2032

  • 市場概要
  • 強直性脊椎炎市場：薬剤別 2022-2032
  • 強直性脊椎炎市場：流通チャネル別 2022-2032
  • 強直性脊椎炎市場：地域別 2022-2032
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東・アフリカの強直性脊椎炎市場 2022-2032

  • 市場概要
  • 強直性脊椎炎市場：薬剤別 2022-2032
  • 強直性脊椎炎市場：流通チャネル別 2022-2032
  • 強直性脊椎炎市場：地域別 2022-2032
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • Novartis
  • AbbVie
  • Janssen
  • Amgen
  • UCB
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • その他の主要企業
図表

List of Tables

  • TABLE 1 Global Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 2 Global Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 3 North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 4 North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 5 U.S. Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 6 U.S. Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 7 Canada Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 8 Canada Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 9 Rest of North America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 10 Rest of North America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 11 UK and European Union Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 12 UK and European Union Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 13 UK Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 14 UK Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 15 Germany Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 16 Germany Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 17 Spain Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 18 Spain Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 19 Italy Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 20 Italy Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 21 France Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 22 France Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 23 Rest of Europe Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 24 Rest of Europe Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 25 Asia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 26 Asia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 27 China Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 28 China Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 29 Japan Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 30 Japan Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 31 India Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 32 India Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 33 Australia Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 34 Australia Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 35 South Korea Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 36 South Korea Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 37 Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 38 Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 39 Brazil Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 40 Brazil Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 41 Mexico Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 42 Mexico Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 43 Rest of Latin America Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 44 Rest of Latin America Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 45 Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 46 Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 47 GCC Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 48 GCC Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 49 Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 50 Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Ankylosing Spondylitis Market By Drug, 2022-2032, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Ankylosing Spondylitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Ankylosing Spondylitis Market: Quality Assurance
  • FIG. 5 Global Ankylosing Spondylitis Market, By Drug, 2023
  • FIG. 6 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023
  • FIG. 7 Global Ankylosing Spondylitis Market, By Geography, 2023
  • FIG. 8 Market Geographical Opportunity Matrix - Global Ankylosing Spondylitis Market, 2023

FIG. 9Market Positioning of Key Ankylosing Spondylitis Market Players, 2023

FIG. 10Global Ankylosing Spondylitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 11 Global Ankylosing Spondylitis Market, By Drug, 2023 Vs 2032, %
  • FIG. 12 Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 Vs 2032, %
  • FIG. 13 U.S. Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 14 Canada Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 15 Rest of North America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 16 UK Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 17 Germany Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 18 Spain Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 19 Italy Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 20 France Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 21 Rest of Europe Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 22 China Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 23 Japan Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 24 India Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 25 Australia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 26 South Korea Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 27 Rest of Asia Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 28 Brazil Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 29 Mexico Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 30 Rest of Latin America Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 31 GCC Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 32 Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
  • FIG. 33 Rest of Middle East and Africa Ankylosing Spondylitis Market (US$ Million), 2022 - 2032
目次
Product Code: 140059-01-24

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine, causing pain, stiffness, and impaired mobility. The ankylosing spondylitis market is expected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2032, propelled by advancements in biological therapies, a patient-centric approach with support programs, and increasing awareness leading to early diagnosis. However, the high cost of biologic therapies poses a notable restraint. Market segmentation reflects the dynamic preferences for AS drugs and regional variations in disease prevalence. Geographically, North America contributes significantly to revenue, while the Asia-Pacific region presents high growth potential. Competitive trends highlight the strategies adopted by major players, including Novartis, AbbVie, and Janssen. These companies leverage innovation, patient support, and global market expansion to maintain a competitive edge. As the ankylosing spondylitis market progresses from 2023 to the forecast period of 2032, addressing cost barriers, sustaining patient-centric approaches, and adapting to regional nuances will be critical for continued success in improving the lives of individuals affected by this chronic inflammatory condition.

Advancements in Biologic Therapies

Advances in biologic therapies, such as TNF inhibitors, have significantly contributed to the treatment landscape of ankylosing spondylitis. Medications like Cosentyx, Humira, and Enbrel have shown efficacy in reducing inflammation, managing symptoms, and improving the overall quality of life for AS patients. The evidence lies in clinical trials and real-world studies that showcase the positive impact of these biological therapies. For instance, studies demonstrate the effectiveness of Cosentyx in achieving sustained improvement in AS symptoms and functionality. As these biologics continue to be at the forefront of AS treatment, their ongoing development and adoption contribute to the market's growth.

Patient-Centric Approach and Support Programs

A patient-centric approach, coupled with comprehensive support programs provided by pharmaceutical companies, has become a driving force in the ankylosing spondylitis market. Companies offering AS treatments, such as Simponi, Remicade, and Cimzia, have initiated support programs to assist patients in accessing medications, managing side effects, and adhering to treatment plans. The evidence lies in patient testimonials and real-world experiences that highlight the positive impact of these support programs on treatment adherence and patient outcomes. As companies continue to prioritize patient well-being and holistic care, the patient-centric approach is anticipated to play a pivotal role in sustaining the market's growth.

Increasing Awareness and Early Diagnosis

The growing awareness of ankylosing spondylitis and efforts to achieve early diagnosis have positively influenced the market. Initiatives by healthcare organizations, patient advocacy groups, and pharmaceutical companies have contributed to increased awareness about the disease's symptoms and the importance of early intervention. The evidence lies in the rise in diagnosed cases and the implementation of screening programs that aim to identify AS at an early stage. Early diagnosis allows for timely intervention and the initiation of effective treatments, leading to better disease management. As awareness campaigns continue to educate both healthcare professionals and the general public, the trend toward early diagnosis is expected to persist, fostering the growth of the AS market.

High Cost of Biologic Therapies

The high cost associated with biologic therapies for ankylosing spondylitis poses a significant restraint on market accessibility. Despite their effectiveness, medications like Cosentyx and Humira come with a substantial financial burden for both patients and healthcare systems. The evidence lies in economic evaluations and studies that highlight the cost-effectiveness challenges of biological treatments. The financial strain may lead to limited access for some patients, potentially hindering optimal disease management. While patient assistance programs exist, addressing the overarching issue of the high cost of biologics is crucial for ensuring equitable access to effective AS treatments.

Drug Segmentation: Cosentyx, Humira, and Enbrel Dominate the Market

In 2023, the ankylosing spondylitis market saw the highest revenue from drugs such as Cosentyx, Humira, and Enbrel. However, the highest Compound Annual Growth Rate (CAGR) during the forecast period (2024-2032) is anticipated from Cimzia. This dynamic growth is driven by the specific attributes and evolving preferences of patients and healthcare providers. Studies and real-world evidence support the efficacy of Cimzia in managing AS symptoms and improving patient outcomes. As the landscape of AS treatment evolves, drug preferences may shift, influenced by factors such as safety profiles and patient response.

North America Remains the Global Leader

Geographically, North America contributed the highest revenue percentage in 2023, reflecting the well-established healthcare infrastructure and high prevalence of ankylosing spondylitis cases. However, the Asia-Pacific region is poised to exhibit the highest CAGR during the forecast period. The evidence lies in the increasing awareness of AS, improving healthcare access, and the evolving landscape of treatment options in Asia-Pacific countries. These geographic trends emphasize the need for tailored strategies to address regional variations in disease prevalence, treatment preferences, and healthcare infrastructure.

Market Competition to Intensify during the Forecast Period

In 2023, major players in the ankylosing spondylitis market included Novartis, AbbVie, Janssen, Amgen, UCB, Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., and others. These companies adopted diverse strategies, including research and development, patient support initiatives, and market expansion efforts. The evidence lies in the continuous development of new treatment options, patient assistance programs, and collaborations with healthcare professionals and patient advocacy groups. As of 2023, the competitive landscape indicates a dynamic market where companies strive to enhance their offerings and support systems. Revenues for 2023 and the expected landscape for the forecast period (2024-2032) reveal a competitive environment where innovation, patient-centered approaches, and global strategies are key determinants of success.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofAnkylosing Spondylitis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Ankylosing Spondylitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

    • Cosentyx
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Others

Distribution Channel

    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Ankylosing Spondylitis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Ankylosing Spondylitis market?
  • Which is the largest regional market for Ankylosing Spondylitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Ankylosing Spondylitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Ankylosing Spondylitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Ankylosing Spondylitis Market
  • 2.2. Global Ankylosing Spondylitis Market, By Drug, 2023 (US$ Million)
  • 2.3. Global Ankylosing Spondylitis Market, By Distribution Channel, 2023 (US$ Million)
  • 2.4. Global Ankylosing Spondylitis Market, By Geography, 2023 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2023

3. Ankylosing Spondylitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Ankylosing Spondylitis Market Vendors
  • 3.2. Strategies Adopted by Ankylosing Spondylitis Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Ankylosing Spondylitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Ankylosing Spondylitis Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Volume and Pricing Analysis, 2022-2032
  • 5.4. Market Segmentation
    • 5.4.1. Cosentyx
    • 5.4.2. Humira
    • 5.4.3. Simponi
    • 5.4.4. Remicade
    • 5.4.5. Enbrel
    • 5.4.6. Cimzia
    • 5.4.7. Others

6. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Volume and Pricing Analysis, 2022-2032
  • 6.4. Market Segmentation
    • 6.4.1. Hospital pharmacy
    • 6.4.2. Retail pharmacy
    • 6.4.3. Online pharmacy

7. North America Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 7.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 7.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 7.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

8. UK and European Union Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 8.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 8.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 8.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

9. Asia Pacific Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 9.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 9.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.4.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.5.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 9.4.1.6.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

10. Latin America Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 10.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 10.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 10.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

11. Middle East and Africa Ankylosing Spondylitis Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
  • 11.3. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
  • 11.4.Ankylosing Spondylitis Market: By Region, 2022-2032, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.1.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.2.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Ankylosing Spondylitis Market: By Drug, 2022-2032, USD (Million)
        • 11.4.1.3.2. Ankylosing Spondylitis Market: By Distribution Channel, 2022-2032, USD (Million)

12. Company Profile

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. AbbVie
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Janssen
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Amgen
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. UCB
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Pfizer, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Eli Lilly and Company
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Merck & Co., Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Other Notable Players
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives